RecruitingPhase 2NCT06402955

Imaging Depression in Parkinson's Disease

Identifying the Neural Basis of Depression in Parkinson's Disease


Sponsor

Yale University

Enrollment

120 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this observational study is to identify targetable neural substrates of depression in Parkinson's Disease for the first time in people with Parkinson's between the ages of 40 and 80, who are experiencing symptoms of depression.


Eligibility

Min Age: 40 YearsMax Age: 80 Years

Plain Language Summary

Simplified for easier understanding

This study is trying to better understand depression in people with Parkinson's disease by using brain imaging scans (PET). It also tests whether ketamine (a fast-acting medication) can help relieve depression symptoms in these patients. **You may be eligible if...** - You are between 40 and 80 years old - You have a clinical diagnosis of Parkinson's disease - If you have depression related to Parkinson's, your symptoms are at least moderate in severity (score of 15 or higher on a standard depression scale) - Women of childbearing age must have a negative pregnancy test **You may NOT be eligible if...** - You have significant memory problems or dementia (MoCA score below 21) - You have another major psychiatric disorder besides depression - You have uncontrolled medical conditions (heart disease, kidney disease, seizures, or brain injury) that could put you at risk - You have had excessive radiation exposure from research studies in the past year - You take certain seizure medications that could affect brain scan results - For the ketamine part: you have uncontrolled high blood pressure (140/90 mmHg or above) or a history of substance abuse Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

RADIATION11C-UCB-J

Radiotracer for imaging

DRUGketamine hydrochloride

There will be a small subset (opt-in) who will receive a single dose of ketamine to determine the ability of ketamine to target these mechanisms and initiate an associated antidepressant response. If the participant is opting into the ketamine arm, the investigators will ask them to come in for one single-dose of ketamine and complete another PET and MRI scan post-ketamine treatment.


Locations(1)

Yale University

New Haven, Connecticut, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06402955


Related Trials